Development of neutralizing antibodies against biotherapeutic agents administered to
prevent or treat various clinical conditions is a longstanding and growing problem faced by …

Procoagulant factor VIII (FVIII) is either produced endogenously under physiologic
conditions, or administered exogenously as a therapeutic hemostatic drug in patients with …

BACKGROUND: The uptake and processing of blood coagulation factor VIII (FVIII) by
antigen-presenting cells and the subsequent presentation of FVIII-derived peptides to CD4+ …

The development of inhibitory anti‐factor VIII (FVIII) antibodies in patients with haemophilia
A following replacement therapy is associated with several types of risk factors. Among …

The development of inhibitory antibodies to therapeutic factor VIII is the major complication
of replacement therapy in patients with hemophilia A. The first step in the initiation of the anti …

In the treatment of hemophilia A, the 20%‐30% risk of developing of anti‐factor VIII (FVIII)
antibodies, or inhibitors, is the dominant concern among healthcare providers. Immune …

Only a fraction of patients with hemophilia A develop a neutralizing antibody (inhibitor)
response to therapeutic infusions of factor VIII. Our present understanding of the underlying …

Abstract Development of neutralizing Abs to blood coagulation factor VIII (FVIII) provides a
major complication in hemophilia care. In this study we explored whether modulation of the …

Factor VIII (FVIII) catabolism has been demonstrated to involve LDL receptor-related protein
(LRP). We have established that antibody fragment KM33 inhibits cofactor function of FVIII …

A large proportion of hemophilia A patients who receive replacement therapy, develop an
immune response toward the infused factor VIII (FVIII). In this review, we discuss recent …